Breakout Ventures Closes $114M Fund III to Back Scientific Innovation Startups

Science has a funny habit. It sits quietly in a lab for years, minding its business, collecting dust on whiteboards and coffee cups. Then one day someone writes a check and suddenly the future gets loud. That is the energy behind Breakout Ventures closing a fresh $114M Fund III. The San Francisco crew built by co founders and Managing Partners Lindy Fishburne and Julia Moore just added more fuel to a machine designed to turn serious science into serious companies. When capital meets curiosity at the right moment, entire industries start paying attention.

Breakout Ventures has always lived in that interesting neighborhood where biology, chemistry, and computation bump into each other like brilliant strangers at a late night conference bar. AI driven biology. Computational chemistry. Diagnostics that move faster than the diseases they are trying to catch. It is the kind of territory where things look impossible until someone proves otherwise and suddenly everyone pretends it was obvious all along.

This new fund brings returning limited partners like Cortes Capital, S Cubed Capital, The Kraft Group, Pinegrove Venture Partners, and an affiliate of LH Capital back to the table. New capital from JIMCO, the investment arm of the Jameel family, and Korea Omega Investment Corporation joins the mix. That blend of returning believers and new conviction usually tells a deeper story. When investors come back for another round it means the first ride delivered something worth repeating.

Inside the firm, the investment bench is stacked with people who understand both the poetry and the physics of building science companies. Dana Watt, PhD brings operator experience from the diagnostics world where real world impact is measured in minutes saved and lives improved. Nima Ronaghi, PhD approaches chemistry with the mindset of someone determined to help scientists step out of the lab and into the founder seat. That combination matters because the hardest part of frontier science is rarely the breakthrough. It is translating the breakthrough into a company that survives the market.

The receipts are already stacking up. Surf Bio turning heads with an acquisition by Halozyme Therapeutics valued up to $400M. Noetik pushing AI powered cancer immunotherapy forward while locking in a major licensing agreement with GSK that started with $50M upfront. Cytovale putting an FDA cleared sepsis diagnostic into emergency departments where speed decides outcomes. Twelve turning captured CO2 into chemicals and sustainable fuel like it is remixing the periodic table for a cleaner economy.

That is the Breakout Ventures pattern. Find the founders who see molecules the way musicians see notes. Back them early. Stay close while the science grows teeth. Fund III just means the speakers get louder from here.